Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KIT | P10721 | 6/20 | 0.61 |
| ▸ | EGFR | P00533 | 10/20 | 0.47 |
| ▸ | RET | P07949 | 2/20 | 0.45 |
| ▸ | KDR | P35968 | 2/20 | 0.45 |
| ▸ | ENPP1 | P22413 | 1/20 | 0.43 |
| ▸ | GAK | O14976 | 1/20 | 0.43 |
| ▸ | SRC | P12931 | 1/20 | 0.43 |
| ▸ | CLK1 | P49759 | 1/20 | 0.43 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.43 |
| ▸ | PDPK1 | O15530 | 2/20 | 0.43 |
| ▸ | LCK | P06239 | 3/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6182709 | 0.79 | KIT (0.59) | KITEGFRRETKDRENPP1 | |
| Hydrochloric Acid SCHEMBL6181793 | 0.78 | KIT (0.57) | KITEGFRRETKDRENPP1 | |
| SCHEMBL15504611 | 0.76 | KIT (1.00) | KITEGFRRETKDRCLK1 | |
| SCHEMBL5569432 | 0.75 | KIT (0.69) | KITEGFRRETKDRENPP1 | |
| SCHEMBL30103402 | 0.75 | PDE5A (0.57) | KITEGFRRETKDRENPP1 | |
| SCHEMBL3166753 | 0.75 | PDE5A (0.57) | KITEGFRRETKDRENPP1 | |
| SCHEMBL3948832 | 0.74 | KIT (0.53) | KITEGFRRETKDRENPP1 | |
| SCHEMBL5568255 | 0.72 | KIT (0.64) | KITEGFRRETKDRENPP1 | |
| SCHEMBL2926080 | 0.72 | KIT (0.67) | KITEGFRRETKDR | |
| SCHEMBL8172203 | 0.71 | KIT (0.59) | KITEGFRRETKDRPDPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200392110-A1 | QUINOLINE DERIVATIVE | ONO PHARMACEUTICAL CO., LTD. (JP) | 2020-12-17 | — | — | US | disclosed |
| EP-3415501-B9 | QUINOLINE DERIVATIVE | ONO PHARMACEUTICAL CO (JP) | 2020-12-02 | — | — | EP | disclosed |
| US-10676462-B2 | Quinoline derivative | ONO PHARMACEUTICAL CO., LTD. (JP) | 2020-06-09 | — | — | US | disclosed |
| EP-3415501-B1 | QUINOLINE DERIVATIVE | ONO PHARMACEUTICAL CO (JP) | 2020-04-08 | — | — | EP | disclosed |
| US-10501442-B2 | Quinoline derivative | ONO PHARMACEUTICALS CO., LTD. (JP) | 2019-12-10 | — | — | US | disclosed |
| US-20190135785-A1 | QUINOLINE DERIVATIVE | ONO PHARMACEUTICAL CO., LTD. (JP) | 2019-05-09 | — | — | US | disclosed |
| US-10208022-B2 | Quinoline derivative | ONO PHARMACEUTICAL CO., LTD. (JP) | 2019-02-19 | — | — | US | disclosed |
| EP-3415501-A1 | QUINOLINE DERIVATIVE | ONO Pharmaceutical Co., Ltd. (JP) | 2018-12-19 | — | — | EP | disclosed |
| US-20180258072-A1 | QUINOLINE DERIVATIVE | ONO PHARMACEUTICAL CO., LTD. (JP) | 2018-09-13 | — | — | US | disclosed |
| US-9994549-B2 | Quinoline derivative | ONO PHARMACEUTICAL CO., LTD. (JP) | 2018-06-12 | — | — | US | disclosed |
| US-20170088542-A1 | QUINOLINE DERIVATIVE | ONO PHARMACEUTICAL CO., LTD. (JP) | 2017-03-30 | — | — | US | disclosed |
| US-9573935-B2 | Quinoline derivative | ONO PHARMACEUTICAL CO., LTD. (JP) | 2017-02-21 | — | — | US | disclosed |
| US-20160168121-A1 | QUINOLINE DERIVATIVE | ONO PHARMACEUTICAL CO., LTD. (JP) | 2016-06-16 | — | — | US | disclosed |
| EP-3026045-A1 | QUINOLINE DERIVATIVE | ONO Pharmaceutical Co., Ltd. (JP) | 2016-06-01 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200392110-A1 | QUINOLINE DERIVATIVE | FLT3, AXL, ERBB2 | KIT 74/4885EGFR 17/4885RET 32/4885 |
| US-10501442-B2 | Quinoline derivative | FLT3, AXL, ERBB2 | KIT 74/4885EGFR 17/4885RET 32/4885 |
| US-20180258072-A1 | QUINOLINE DERIVATIVE | FLT3, AXL, ERBB2 | KIT 74/4885EGFR 17/4885RET 32/4885 |
| US-10208022-B2 | Quinoline derivative | FLT3, AXL, ERBB2 | KIT 74/4885EGFR 17/4885RET 32/4885 |
| US-20160168121-A1 | QUINOLINE DERIVATIVE | FLT3, AXL, ERBB2 | KIT 81/4885EGFR 24/4885RET 29/4885 |
| US-20170088542-A1 | QUINOLINE DERIVATIVE | FLT3, AXL, ERBB2 | KIT 74/4885EGFR 17/4885RET 32/4885 |
| US-10676462-B2 | Quinoline derivative | FLT3, AXL, ERBB2 | KIT 74/4885EGFR 17/4885RET 32/4885 |
| US-20190135785-A1 | QUINOLINE DERIVATIVE | FLT3, AXL, ERBB2 | KIT 74/4885EGFR 17/4885RET 32/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.